Abstract:BackgroundLarge-cohort proteomics analysis using mass spectrometry is a powerful approach to discover and validate new biomarkers. In combination with clinical data and computational analysis, large-cohort proteomics study brings opportunities in improving early diagnosis, refining patient stratification, and predicting/monitoring treatment response. Yet, to achieve meaningful biological insights in large-cohort studies, robust, reproducible, and comprehensive proteome profiling in a high-throughput manner still remains challenging. Here, we use a high-resolution accurate mass (HRAM) Oribtrap Astral platform to enable high-quality and robust protein quantification across thousands of LC-MS/MS analyses. With a throughput of 100 samples/day, we can reproducibly profile ∼9000 proteins from human cell line and ∼800 proteins from undepleted plasma across multiple instruments and more than 10 consecutive days in a 24/7 operation mode.MethodsExperiments were performed on multiple Orbitrap Astral mass spectrometers with and without FAIMS Pro interface. Chromatographic separations were performed using a trap/elute method on Vanquish Neo system at a 11-minute gradient and a flow rate of 1ul/min, resulting in a throughput of 100 samples/day. Undepleted plasma digest was analyzed in a 24/7 mode for > 1000 injections on each LC-MS/MS setup. In addition, HeLa digest as quality control (QC) was analyzed every 12hours. The Oribtrap Astral platform was operated in data-independent acquisition (DIA) mode using a full scan with m/z 380-980, and DIA MS/MS scans with an isolation window of 2Th. Resulting DIA raw files were automatically transferred and processed using Chimerys in a beta version of Proteome Discoverer software.ResultsMultiple LC-MS/MS systems were operated in DIA mode either with or without FAIMS Pro device in a 24/7 operation mode at a throughput of 100SPD. Undepleted plasma digest was analyzed with >1000 injections on each LC-MS/MS setup. To monitor the baseline performance, HeLa digest served as QC were analyzed periodically every 12 hours with 3 technical replicates each time. To effectively manage and analyze these thousands of data files generated, we developed an automated data transfer and analysis pipeline. Automatically, the resulting DIA raw data files were immediately transferred to a server, then processed by state-of-the-art intelligent search algorithm Chimerys. Benefiting from the ultra-high scan speed of up to 200Hz on the Orbitrap Astral mass spectrometer, a much narrower isolation window width of 2Th was applied in the DIA method, comparing to 10-20Th on the classic DIA method. As a result, ∼9000 proteins from HeLa digest and ∼800 proteins from undepleted plasma digest were identified within only a 11-minutes gradient, respectively. More than 80% of the plasma proteins were reproducibly identified and quantified from all the runs on each LC-MS/MS setup, indicating a great reproducibility from run-to-run longitudinally. Stable and robust peptide quantitation was observed by extracting peptides with high, medium, and low abundant across the runs. Importantly, QC showed no performance degradation throughout the entire study, indicating high robustness of the entire LC-MS/MS setup.ConclusionsOrbitrap Astral mass platform can comprehensively analyze the proteome of >1000s of sample robustly and reproducibly in a high-throughput manner, addressing the needs in large-cohort studies.

Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer

A novel hybrid high speed mass spectrometer allows rapid translation from biomarker candidates to targeted clinical tests using 15N labeled proteins

B-249 Assessing Targeted Mass Spectrometry Assay Performance for Putative Biomarker Proteins on a New Hybrid Nominal Mass Instrument

Hybrid Quadrupole Mass Filter Radial Ejection Linear Ion Trap and Intelligent Data Acquisition Enable Highly Multiplex Targeted Proteomics

A workflow for targeted proteomics assay development using a versatile linear ion trap

Enhanced Detection of Low Abundance Human Plasma Proteins Using a Tandem IgY12-SuperMix Immunoaffinity Separation Strategy

Data Independent Acquisition to Inform the Development of Targeted Proteomics Assays Using a Triple Quadrupole Mass Spectrometer

Progress in Targeted Mass Spectrometry (parallel Accumulation-Serial Fragmentation) and Its Application in Plasma/Serum Proteomics.

Crossing the Halfway Point: Aptamer-Based, Highly Multiplexed Assay for the Assessment of the Proteome

Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens

A rapid methods development workflow for high-throughput quantitative proteomic applications

Coupling Microdroplet-Based Sample Preparation, Multiplexed Isobaric Labeling, and Nanoflow Peptide Fractionation for Deep Proteome Profiling of the Tissue Microenvironment

Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry

A Comprehensive LC–MS Metabolomics Assay for Quantitative Analysis of Serum and Plasma

Development and Evaluation of a Parallel Reaction Monitoring Strategy for Large-Scale Targeted Metabolomics Quantification.

B-146 Unlocking the potential of large-cohort proteomics studies with the Orbitrap Astral mass platform

Development of high throughput dispersive LC-ion mobility-TOFMS techniques for analysing the human plasma proteome.

Assessment of a high-throughput mass spectrometry method to accelerate biomarker discovery in clinical cancer cohorts using volumetric absorptive microsampling (VAMS) devices.

Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications

Enhanced Sample Multiplexing-Based Targeted Proteomics with Intelligent Data Acquisition

An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients